: "arise: a phase 3 randomized trial of erenumab for episodic migraine."
.
.
.
.
.
.
updated: may 18, 2018, 10.36 am ist
.
erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
pharma exports can cross bn by 2020: chief of pharmexcil